March 27, 2018
At the extraordinary general meeting of the Pharmstandard JSC shareholders, taking place on the 15th of March, 2018, it was decided to reorganize the company by separating out Vektor – BioPharm, a new joint-stock company. The process of assets formation of the newly created company is mainly carried out at the expense of non-core assets and monetary funds of Pharmstandard JSC. At the same time, investment activity is defined as the main course of action for Vektor – BioPharm. The registration of a new legal entity is set to July this year.
"The allocation non-core assets will allow Pharmstandard to focus its efforts on the main line of business – production of pharmaceuticals," said Grigoriy Potapov, Director General of Pharmstandard JSC.
Since Egor Kulkov has just before lost his beneficiary status of Pharmstandard JSC as a result of changes in members of Augment Investments Limited, the controlling shareholder of Pharmstandard JSC, Viktor Kharitonin, following the reorganization results, will be the sole beneficiary of both companies.